Compare · CI vs CSTL
CI vs CSTL
Side-by-side comparison of The Cigna Group (CI) and Castle Biosciences Inc. (CSTL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and CSTL operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $78.83B, about 125.6x CSTL ($627.8M).
- Over the past year, CI is down 5.2% and CSTL is up 7.3% - CSTL leads by 12.5 points.
- CSTL has been more active in the news (18 items in the past 4 weeks vs 3 for CI).
- CI has more recent analyst coverage (25 ratings vs 5 for CSTL).
- Company
- The Cigna Group
- Castle Biosciences Inc.
- Price
- $297.81+1.07%
- $20.68-1.43%
- Market cap
- $78.83B
- $627.8M
- 1M return
- -0.93%
- +14.13%
- 1Y return
- -5.22%
- +7.32%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 3
- 18
- Recent ratings
- 25
- 5
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Castle Biosciences Inc.
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Latest CI
- EVP, Global CIO Koka Durga Prasad covered exercise/tax liability with 729 shares, decreasing direct ownership by 10% to 6,552 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Kurian George
- The Cigna Group downgraded by Barclays with a new price target
- The Cigna Group downgraded by Deutsche Bank with a new price target
- Chairman & CEO Cordani David exercised 212,543 shares at a strike of $170.34 and sold $59,114,186 worth of shares (201,878 units at $292.82) as part of a pre-agreed trading plan, increasing direct ownership by 23% to 57,766 units (SEC Form 4)
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure
- The Cigna Group Announces Appearance at the BofA Securities 2026 Health Care Conference
- Kayne Anderson Energy Infrastructure Fund Announces Appointment of Michael J. Hennigan as New Independent Director
- SEC Form 144 filed by The Cigna Group
- SEC Form 10-Q filed by The Cigna Group
Latest CSTL
- Pres. & Chief Exec. Officer Maetzold Derek J exercised 6,214 shares at a strike of $2.39 and sold $205,149 worth of shares (9,836 units at $20.86) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Castle Biosciences Inc.
- SEC Form 4 filed by Director Olson Tiffany
- SEC Form 4 filed by Director Goldberg Ellen
- SEC Form 4 filed by Director Harrison Miles
- SEC Form 4 filed by Director Cotton Rodney
- SEC Form 4 filed by Director Caple Kim
- SEC Form 4 filed by Director Bradbury Daniel
- SEC Form 4 filed by Director Cole G Bradley
- Castle Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders